UroGen Pharma Ltd. - 8-K Filing

UroGen Pharma Ltd. entered into a settlement and license agreement with Teva Pharmaceuticals on June 2, 2026, resolving patent litigation related to Jelmyto® (mitomycin). Under the terms of the agreement, Teva will be granted a non-exclusive license to sell its generic version of Jelmyto starting September 15, 2030, if approved by the FDA. All ongoing U.S. District Court patent litigation regarding Jelmyto has been terminated. (Items: 8.01 Other Events)

SEC EDGAR · June 2, 2026, 12:05 UTC

Tickers: $URGN

Read the full article at SEC EDGAR

More Regulatory news

REGIONAL HEALTH PROPERTIES, INC - 8-K Filing SEC EDGAR · November 12, 2026, 15:09 UTC
Bitwise Avalanche ETF - 8-K Filing SEC EDGAR · November 12, 2026, 15:06 UTC
MiNK Therapeutics, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 15:05 UTC
Future Vision II Acquisition Corp. - 10-Q Filing SEC EDGAR · November 12, 2026, 15:00 UTC
THUNDER MOUNTAIN GOLD INC - 10-Q Filing SEC EDGAR · November 12, 2026, 15:00 UTC
MiNK Therapeutics, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:49 UTC
SusGlobal Energy Corp. - 10-Q Filing SEC EDGAR · November 12, 2026, 14:42 UTC
Ideal Power Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:25 UTC
DIGI INTERNATIONAL INC - 8-K Filing SEC EDGAR · November 12, 2026, 14:23 UTC
ZeroStack Corp. - 8-K Filing SEC EDGAR · November 12, 2026, 14:22 UTC